Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?

Core Insights - Eli Lilly has experienced a significant 55% increase in stock price in the first half of the year, driven by double-digit revenue growth and strong demand for its weight-loss drugs Mounjaro and Zepbound [1][2] - The weight-loss drug market is projected to reach $100 billion by 2030, indicating substantial growth potential for Lilly [1] - Lilly's recent approvals and ongoing clinical trials for new weight-loss drugs position the company favorably in a competitive market [4][5] Company Performance - Lilly's weight-loss portfolio, particularly Mounjaro and Zepbound, has become a key revenue driver, with Zepbound generating over $517 million in its first full quarter [3] - The company has invested over $18 billion in infrastructure since 2020 to meet the soaring demand for its products [4] - Four other products in Lilly's portfolio also reported double-digit revenue growth in the recent quarter, showcasing the company's overall strong performance [6] Future Growth Potential - Lilly is pursuing additional approvals, including tirzepatide for obstructive sleep apnea, which could enhance its market position by unlocking Medicare coverage for Zepbound [6][7] - The recent approval of Kisunla for early symptomatic Alzheimer's disease adds to Lilly's innovative product offerings, distinguishing it in the Alzheimer's treatment landscape [7] - The company's current valuation at 66 times forward earnings reflects its growth potential, with a target stock price of $1,000 representing a market cap of $900 billion [8]